



PUBLICATION OF THE 2021 ANNUAL FINANCIAL REPORT, 2021 CONSOLIDATED NON-FINANCIAL STATEMENT AND MAY 2022 MEETING DOCUMENTATION

Verdellino (BG), 31 March 2022

Fine Foods & Pharmaceuticals N.T.M. S.p.A. (hereafter referred to as "Fine Foods" or the "Company") announces that the Annual Financial Report, including the Consolidated Financial Statements as of 31 December 2021, the Company draft Financial Statements as of 31 December 2021, the Management Report, the certifications under Article 154-bis, paragraph 5 of Legislative Decree 24 February 1998, no. 58 ("TUF"), and the Reports prepared by the Auditing Company and the Board of Statutory Auditors, are available to the public at the Company's registered office, on the Company's website at www.finefoods.it, in the Governance/Shareholders' Meetings section and on the authorised storage system 1info managed by Computershare S.p.A. at www.1info.it.

The 31 December 2021 Consolidated Non-Financial Statement prepared under Legislative Decree no. 254 of 30 December 2016, accompanied by the Auditing Company Report, and the Report on Corporate Governance and Ownership Structure under Article 123-bis of the TUF are available using the same methods.

The Financial Statements and summary reports of Fine Foods' subsidiaries under Article 2429, paragraphs 3 and 4, of the Italian Civil Code, will be made public under current regulations' methods and deadlines.

This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Euronext STAR Milan, is an Italian independent Contract Development & Manufacturing Organisation (CDMO). It develops and manufactures contract products for the pharmaceutical and nutraceutical industries. Fine Foods is also active in the cosmetics, biocides and medical devices industries with its acquisition of Pharmatek-PMC and the most recent Euro Cosmetic acquisition.

Founded in 1984, from a pharmaceutical and nutraceutical synergy, its main objective is to research and develop quality and innovation on behalf of its customers. With € 193 million revenue in 2021 and an 11 per cent CAGR over the last decade, it is a growing and future-oriented company.

The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the company to fully develop its intrinsic potential.



For information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Investor Relations

tel. +39 035 4821382

ir@finefoods.it

CDR Communication

Media Relations

Marianna Tremolada

marianna.tremolada@cdr-communication.it